Capricor Therapeutics, Inc. (CAPR) P/S ratio
The P/S ratio of Capricor Therapeutics, Inc. (CAPR) was 21.8× at the end of fiscal 2024 (December 31, 2024). That is 319.6% higher than the 5.2× of fiscal 2023. Figures as of 18 Nov 2026, 04:19 UTC, from the company's filings with the SEC and Yahoo Finance.
Key facts
- P/S ratio, fiscal 2024
- 21.8×
- Change on fiscal 2023
- +319.6%
- Highest on record
- 276.2×fiscal 2021
- Lowest on record
- 4.7×fiscal 2019
- Fiscal years on record
- 92016–2024
Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.
Capricor Therapeutics, Inc. P/S ratio, in more detail
Across the 9 fiscal year-ends on record (2016–2024), the highest was 276.2× in fiscal 2021 and the lowest 4.7× in fiscal 2019.
P/S ratio at each fiscal year-end
Capricor Therapeutics, Inc. P/S ratio, year by year
| Fiscal year | P/S ratio | Change | Year ended | Share price at year-end | Revenue per share |
|---|---|---|---|---|---|
| 2025 | — | — | $28.86 | — | |
| 2024 | 21.8× | 319.6% up | $13.80 | $0.63 | |
| 2023 | 5.2× | 86.0% down | $4.89 | $0.94 | |
| 2022 | 37.1× | 86.6% down | $3.86 | $0.10 | |
| 2021 | 276.2× | 60.5% up | $2.93 | $0.01 | |
| 2020 | 172.1× | 3,542.0% up | $3.43 | $0.02 | |
| 2019 | 4.7× | 34.5% down | $1.28 | $0.27 | |
| 2018 | 7.2× | 54.5% down | $4.10 | $0.57 | |
| 2017 | 15.9× | 28.6% up | $15.80 | $1.00 | |
| 2016 | 12.3× | — | $26.60 | $2.16 | |
| 2015 | — | — | $30.70 | — | |
| 2014 | — | — | $37.50 | — | |
| 2013 | — | — | $32.50 | — | |
| 2012 | — | — | $25.00 | — | |
| 2011 | — | — | $275.00 | — | |
| 2010 | — | — | $310.00 | — | |
| 2009 | — | — | $605.00 | — | |
| 2008 | — | — | $425.00 | — | |
| 2007 | — | — | $2,750.00 | — |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
The P/S ratio is the share price divided by revenue per share — the same thing as market value divided by revenue — taken at each fiscal year-end.
How to read it
It prices each unit of sales and still works when there is no profit; what counts as high depends on the margin those sales earn.
Capricor Therapeutics, Inc., figure by figure
- Capricor Therapeutics, Inc. market cap
- Capricor Therapeutics, Inc. revenue
- Capricor Therapeutics, Inc. earnings
- Capricor Therapeutics, Inc. earnings per share (EPS)
- Capricor Therapeutics, Inc. P/E ratio
- Capricor Therapeutics, Inc. P/B ratio
- Capricor Therapeutics, Inc. free cash flow
- Capricor Therapeutics, Inc. operating margin
- Capricor Therapeutics, Inc. dividend
- Capricor Therapeutics, Inc. shares outstanding
- Capricor Therapeutics, Inc. total debt
- Capricor Therapeutics, Inc. cash on hand
- Capricor Therapeutics, Inc. total assets
- Capricor Therapeutics, Inc. return on equity (ROE)
- Capricor Therapeutics, Inc. return on invested capital (ROIC)
Capricor Therapeutics, Inc. (CAPR) overview: price, valuation and scorecard
Capricor Therapeutics, Inc. P/S ratio: questions and answers
What is Capricor Therapeutics, Inc.'s P/S ratio?
The P/S ratio of Capricor Therapeutics, Inc. (CAPR) was 21.8× at the end of fiscal 2024 (December 31, 2024). That is 319.6% higher than the 5.2× of fiscal 2023.
What are the highest and lowest P/S ratio figures on record for Capricor Therapeutics, Inc.?
Across the 9 fiscal year-ends on record (2016–2024), the highest was 276.2× in fiscal 2021 and the lowest 4.7× in fiscal 2019.
How is Capricor Therapeutics, Inc.'s P/S ratio calculated?
The P/S ratio is the share price divided by revenue per share — the same thing as market value divided by revenue — taken at each fiscal year-end.
Share prices are Yahoo Finance's monthly closes: a fiscal year-end is paired with the close of the month it falls in, and today's quote may be delayed. Fiscal years are named for the calendar year they end in.
Learn: P/S ratio
All stocks guides →- P/E ratio explained: what a high or low figure means
The price-to-earnings (P/E) ratio is a share's price divided by its earnings per share. A stock at $100 earning $5 a share has a P/E of 20: buyers pay $20 for each dollar of yearly profit. A high P/E usually means the market expects profit to grow; a low one can mean doubt, not a bargain.
- Revenue vs earnings vs free cash flow: what each tells you
Revenue is everything a company sold in a period. Earnings, or net income, is what remains after every cost, interest and tax. Free cash flow is the cash operations brought in minus spending on long-lived assets. Revenue shows size and demand, earnings show profitability, and free cash flow shows how much cash the business can actually hand out.
- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
Cite this page
Funkfolio, “Capricor Therapeutics, Inc. (CAPR) P/S ratio”, data as of 18 November 2026. https://funkfolio.com/stock/CAPR/ps-ratio
Underlying data: the company's filings with the SEC and Yahoo Finance.